A novel process for mutation detection using uracil DNA-glycosylase by Vaughan, Patrick & McCarthy, Tommie V.
Title A novel process for mutation detection using uracil DNA-glycosylase
Author(s) Vaughan, Patrick; McCarthy, Tommie V.
Publication date 1998
Original citation Vaughan, P. and McCarthy, T. V. (1998) 'A novel process for mutation
detection using uracil DNA-glycosylase', Nucleic Acids Research, 26(3),
pp. 810-815. doi: 10.1093/nar/26.3.810
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/26.3.810
http://dx.doi.org/10.1093/nar/26.3.810
Access to the full text of the published version may require a
subscription.
Rights © 1998, Oxford University Press
Item downloaded
from
http://hdl.handle.net/10468/5037
Downloaded on 2018-08-23T19:02:56Z
 1998 Oxford University Press810–815 Nucleic Acids Research, 1998, Vol. 26, No. 3
A novel process for mutation detection using uracil
DNA-glycosylase
Patrick Vaughan and Tommie V. McCarthy* 
Department of Biochemistry and National Food Biotechnology Centre, University College, Cork, Ireland
Received September 12, 1997; Revised and Accepted December 9, 1997
ABSTRACT
A novel process is presented for the detection of
known mutations and polymorphisms in DNA. This
process, termed glycosylase mediated polymorphism
detection (GMPD) involves amplification of the target
DNA using three normal dNTPs and a fourth modified
dNTP, whose base is a substrate for a specific
DNA-glycosylase once incorporated into the DNA. The
work described here utilises uracil DNA-glycosylase
as the specific glycosylase and dUTP as the modified
dNTP. Primers are designed so that during extension,
the position of the first uracil incorporated into the
extended primers differs depending on whether a
mutation is present or absent. Subsequent glycosylase
excision of the uracil residues followed by cleavage of
the apyrimidinic sites allows detection of the mutation
in the amplified fragment as a fragment length
polymorphism. Variation in the sizes of the fragment
length polymorphisms generated, can be readily
achieved through the use of inosine bases in place of
adenine bases in the upper and/or lower primers. The
GMPD process is also adaptable to solid phase analysis.
The use of the process for detection of mutations in the
RYR1 and CFTR genes is demonstrated. Overall, the
simplicity, specificity, versatility and flexibility of the
GMPD process make it an attractive candidate for both
small and large scale application in mutation detection
and genome analysis.
INTRODUCTION
Detection of multiple different mutations and polymorphisms at
specific locations in DNA is of prime importance for genetic
diagnosis, molecular genotyping, molecular epidemiology and
rapid identification of various traits in eukaryotic and prokaryotic
organisms. The surge in genome research over the last decade and
particularly since the advent of PCR has identified numerous
mutations of significance for human and animal health and
numerous mutations of commercial value (1). Mutation detection
technology has progressed with advances in genome research and
a variety of methods have been described for detection of known
mutations. However, many of these methods suffer from
drawbacks that limit their utility and there is considerable interest
in the development of improved detection systems. An optimum
system for mutation detection needs to offer specificity, sensitivity,
flexibility, versatility and ease of use. In addition an optimum system
should also be robust, allow rapid and high throughput of samples,
be amenable to automation and be cost effective.
Here, we describe a novel process for mutation detection referred
to as glycosylase mediated polymorphism detection (GMPD) which
exploits the use of highly specific DNA-glycosylase enzymes to
excise substrate bases incorporated into amplified DNA.
In this work, the DNA-glycosylase used is uracil DNA-glyco-
sylase (UDG). UDG is a highly specific DNA repair enzyme which
cleaves the N-glycosidic bond between the base uracil and the sugar
deoxyribose in a DNA molecule and generates an apyrimidinic (AP)
site. The AP site can subsequently be cleaved chemically or
enzymatically (2,3). The enzyme recognises and releases uracil
from both single stranded and double stranded DNA efficiently
(4,5). Uracil can be generated readily in DNA through the
incorporation of deoxyuridine triphosphate (dUTP) or through
chemical or heat induced deamination of cytosine residues in DNA
(6–8).
Here, we demonstrate the use of the GMPD process for accurate
and specific detection of several point mutations in the RYR1 gene
causal of the inherited disorder malignant hyperthermia and the
∆F508 deletion mutation in the CFTR gene causal of cystic fibrosis.
MATERIALS AND METHODS
Oligonucleotide labelling and DNA amplification and dUTP
incorporation
Human genomic DNA was prepared from blood and muscle
samples as described previously (10). Primers (gel purified)
(60 pmol) were end labeled by incubation with T4 polynucleotide
kinase (New England Biolabs) in appropriate buffer and 50 µCi
[γ-32P]ATP (3000 Ci/mmol) (New England Nuclear) for 30 min at
37C followed by ethanol precipitation to remove unused labelled
nucleotide. Using end-labelled primers, the genomic DNA sample
was amplified by PCR under standard conditions as follows: 200 ng
genomic DNA from the affected patient as template, 0.2 mM dATP,
dCTP, dGTP and dUTP, 6 pmol of the labelled diagnostic primer and
non-labeled primer and 1 U of Taq polymerase bringing the total
volume to 20 µl. Annealing temperatures and MgCl2 concentrations
varied with each different amplification (data not shown). PCR
amplification using labelled deoxyribonucleotides was carried out as
follows: 100 ng genomic DNA from the affected patient as
template, 0.02 mM dATP, dCTP, dGTP and dUTP, 1 µCi
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[α-32P]dCTP, 3 pmol of both primers and 1 U of Taq polymerase
bringing the total volume to 10 µl.
Glycosylase mediated cleavage of DNA
The reaction mixture bearing the amplified target nucleic acid is
then treated with Exonuclease I (ExoI) (Amersham Life Sciences)
to digest the primers not extended in the amplification step. This
is achieved by incubating 3 µl of the PCR reaction with 0.5 U of
ExoI at 37C for 30 min. The exonuclease was subsequently heat
inactivated by incubating the reaction at 80C for 15 min.
Escherichia coli UDG (0.5 U) (New England Biolabs) was then
added and the incubation continued at 37C for 30 min.
Following treatment with UDG, the AP sites generated in the
amplified product were cleaved to completion by adding NaOH
to a final concentration of 0.05 M and heating the mixture for
15 min at 95C. Under these conditions, cleavage occurs on the
5′ side of each AP site. The reaction was then neutralised by
addition of Tris base to 30 mM final concentration. Both ExoI and
UDG are diluted in buffer containing 0.07 M HEPES–KOH, pH
8.0, 1 mM EDTA, 1 mM DTT and 50% glycerol.
An equal volume of formamide loading dye (90% formamide,
0.025% Bromophenol blue, 0.025% Xylene cylanol) was added to
the sample which was then heated at 85C for 5 min. The sample
was then loaded onto a 20% denaturing (7 M urea) polyacrylamide
gel and electrophoresis was carried out for 3–4 h at 400 V for size
analysis of the cleaved products in the sample. Following
electrophoresis, autoradiography was carried out by exposing the gel
directly to X-ray photographic film for 12 h at –70C.
Solid phase GMPD
Solid phase detection of mutations was carried out as follows:
PCR amplification using labelled deoxyribonucleotides and a
biotinylated primer was carried out using 100 ng genomic DNA
from each individual as template, 0.2 mM dATP, dGTP and
dUTP, 0.02 mM dCTP and 1 µCi [α-32P]dCTP, 3 pmol of both
primers and 1 U of Taq polymerase bringing the total volume to
10 µl. The amplified DNA was treated with ExoI as described
above. The sample was then divided into two aliquots (5.5 µl) and
1 µl UDG (0.5 U/µl) was added to one of the aliquots (A) and 1 µl
H2O added to the other (B) and both were incubated at 37C for
30 min. An aliquot (1 µl) of NaOH was then added (0.15 M final)
and the samples were incubated at 95C for 15 min. The reaction
was then neutralised by addition of 4.55 µl of 0.2 M HCl and the
samples brought to 37 µl final volume and 1 M NaCl
concentration upon addition of NaCl and TE buffer. The
immobilisation was carried out using streptavidin coated beads
(Dynabeads M-280 Streptavidin). Three µl of washed beads
(10 mg beads/ml, washed in 1× B+W buffer, i.e. 10 mM
Tris–HCl, pH 7.5, 1 mM EDTA and 1 M NaCl according to
manufacturer’s instructions) was added to each sample and
incubated at room temperature for 5 min. The beads were then
immobilised using a Dynal MPC-E (Magnetic Particle
Concentrator for microfuge tubes) and the supernatant discarded.
The beads were incubated with 40 µl 0.15 M NaOH and incubated
at room temperature for 5 min. The supernatant was removed
using MPC-E. The immobilised single stranded biotinylated
DNA was then washed with 40 µl 1× B+W buffer and
subsequently resuspended in 100 µl H2O. The amount of 32P
remaining attached to the beads was quantified by Cerenkov
scintillation counting. The results are expressed as a percentage and
calculated as the amount of radioactive DNA remaining bound
following GMPD processing (c.p.m. in A) divided by the total
amount of radioactive DNA bound for each sample (c.p.m. in B).
RESULTS
Glycosylase mediated polymorphism detection (GMPD)
The GMPD process presented involves the use of UDG to detect
the presence or absence of a uracil residue at a specific location
in an amplified DNA molecule. A schematic diagram of the
process is shown in Figure 1. The objective is to determine if a
particular mutation (C to T) is present or absent at a specific
location in a DNA test sample. PCR amplification of the sample
is carried out using dGTP, dATP, dCTP and dUTP. The upper
primer is labelled and serves as the diagnostic primer here. It is
designed so that when it is extended during the amplification
reaction, the first dUTP residue incorporated into the extended
primer is at the mutation site if the mutation is present, or distal
to the site if the mutation is absent. The oligonucleotide primers
contain dG, dA, dT and dC and consequently are resistant to
cleavage by UDG. Following PCR amplification of the test
sample, the uracil bases are released by incubation of the
amplified product with UDG generating AP sites. The phosphate
linkages of the DNA at the resulting AP sites are then cleaved
chemically or enzymatically. If a uracil base is present at the
mutation site, the labelled upper strand will be cleaved to a
specific length i.e., Yn, determined by the distance between the
primer and the mutation site. If a uracil base is absent at the site,
the labelled strand will be cleaved at the next position 3′ of the site
where the first uracil is incorporated. Therefore, depending on
whether a uracil base is present or absent at the mutation site, the
extended labelled primer will be cleaved at, or 3′ of the site, and
result in labelled fragments that can be distinguished by size (Xn
or Yn). Such a size difference can readily be detected by existing
DNA sizing technologies such as denaturing polyacrylamide gel
electrophoresis and autoradiography or fluorescence imaging. In
the schematic diagram shown, the presence of a band of Yn in
length identifies the presence of the C to T mutation whereas the
Xn band identifies the normal allele. A sample displaying both
bands of Xn and Yn identifies the heterozygous state (Fig. 1).
Detection of the G1021A mutation in RYR1 gene
We have used the GMPD process to detect a common point
mutation (a G to A transition at position 1021) in the ryanodine
receptor gene (RYR1) in the autosomal dominant disorder
malignant hyperthermia (MH). MH predisposes individuals to an
adverse reaction to the common inhalational anaesthetics agents
and is potentially fatal (9). Patients are classified as MH
susceptible (MHS) or MH normal (MHN) based on the response
of skeletal muscle samples in an in vitro contracture test to
caffeine and the anaesthetic halothane. The GMPD process was
used here to detect the RYR1 G1021A in a well characterised
MHS pedigree (10). As the G1021A mutation does not cause the
gain or loss of a restriction site, it was previously shown to
segregate with MH susceptibility in this pedigree by SSCP
analysis (11). The sequence of the RYR1 gene from nt 1001 to
1044 is shown in Figure 2A. In this case the mutation results in
a G to A base change in the upper strand at position 1021 and a
corresponding C to T base change in the lower strand. Two
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Figure 1. Schematic representation of the GMPD process using a labelled (*)
upper (diagnostic) and unlabelled lower primer. Primers are denoted by arrows.
The mutation site (C/G to T/A) is shown in bold type. Sites of dUMP
incorporation during extension of the diagnostic primer are shown for the upper
strand only and denoted by ‘U’.
primers were designed to amplify the mutated region as a 44 bp
DNA segment. The lower primer (21 nt) was designed so that in
the mutant allele, there is an extension of 2 nt before the
incorporation of the first dUMP at position 1021 while in the
normal allele the first dUMP to be incorporated is 5 nt
downstream of the 3′-end of this primer at position 1019. The
lower primer was 32P end-labelled and served as the diagnostic
primer. Thus, amplification of the region followed by analysis of
the fragments generated by UDG mediated cleavage should allow
detection of the normal and mutant alleles as 25 and 23 nt
fragments respectively. Figure 2B shows the result of the analysis
of the members of the affected family. Before digestion with
uracil DNA-glycosylase and AP site cleavage, the PCR products
were incubated with ExoI. This is a single strand specific
exonuclease and digests any unused primer including any
non-specific single stranded DNA present. This can be seen by
comparing lanes 1–8 with lane 10 that was not treated with ExoI.
MHS individuals 1, 4, 7 and 8 display a 25 and a 23 nt fragment,
showing that these individuals are heterozygous for the mutation.
The 25 nt fragment only, is present in MHN individuals 2, 3, 5 and
Figure 2. GMPD of the MHS RYR1 G1021A mutation. (A) DNA sequence of
the wild-type RYR1 gene from nt 1001 to 1044. Primers used in amplification
of this region are enclosed in a box. The asterisks denotes the end labelled
diagnostic primer. The G1021A mutation site (G/C to A/T) is indicated by
larger bold type. (B) Analysis of fragments generated from the RYR1 region
1001–1044 amplified from members of a MH pedigree following UDG
mediated cleavage. In the pedigree, open circles and squares denote MHN
individuals and closed circles and squares denote MHS individuals. Samples
were subjected to denaturing polyacrylamide gel electrophoresis and visualised
by autoradiography. Lane 9 shows the labelled diagnostic primer. Lane 10
shows the full length PCR product prior to cleavage. The band denoted ‘ds’ is
due some of the undigested PCR remaining in the double stranded form
6 showing that they are homozygous for the normal allele
(Fig. 2B). Results from the GMPD correspond with detection of
the G1021A mutation in this family by direct DNA sequencing
and SSCP analysis (10).
Detection of CFTR ∆F508 deletion mutation using the GMPD
process
Insertion and deletion type mutations also occur commonly in
genetic disease. The GMPD process can also be used for detection
of these types of mutations and its application is shown here for
analysis of individuals homozygous and heterozygous for the
common CTT deletion mutation (∆F508) in the CFTR gene in
cystic fibrosis (12,13). The DNA sequence surrounding the site
of this mutation is shown in Figure 3A. Two primers were chosen
to amplify a 54 bp section of the CFTR gene encompassing the
∆F508 (deletion of CTT) mutation by PCR. In this case, we chose
the lower primer as the diagnostic primer. Analysis of the
amplified 54 bp product from a homozygous normal individual
following glycosylase mediated cleavage generates a 34 nt
fragment while a 31 nt fragment is present in the homozygous
affected individual. Both the 34 and 31 nt fragments are present
in the heterozygous carrier (Fig. 3B, lanes 1, 2 and 3). The ∆F508
deletion can also be detected using end-labelled upper primer and
will produce a 22 and a 21 nt fragment for the normal and mutant
alleles respectively (data not shown). An alternative labelling
approach for detecting the normal and mutant alleles was also
used i.e., internal labelling by incorporation of an [α-32P]dNTP
during DNA amplification. In this case, [α-32P]dCTP was
utilised, therefore, during extension of the primers, the 54 bp PCR
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Figure 3. GMPD of the CFTR ∆F508 mutation. (A) Sequence of PCR
amplified region of wild-type CFTR gene from nt 1632 to 1685. Primers used
for amplification of this region are enclosed in a box. The asterisks denote the
32P end-labelled diagnostic primer. The ∆F508 mutation site (deletion of CTT)
is indicated by larger bold type. (B) Analysis of end labelled fragments
generated from the amplified CFTR region 1632–1685 from a CF heterozygous
carrier (Nn, lane 1), a CF homozygous affected (nn, lane 2) and homozygous
normal (NN, lane 3) individual following UDG mediated cleavage. Analysis of
internally labelled (using [α-32P]dCTP) fragments for the heterozygous (lane
4), homozygous affected (lane 5) and homozygous normal (lane 6) individuals.
The full length PCR product (54 nt) is shown in lane 7.
product was labelled at cytosine residues. Following analysis of
the glycosylase mediated cleavage products, all fragments
containing C residues will be detected. Individuals carrying two
normal alleles display bands of 34 and 22 nt (Fig. 3B, lane 6). An
individual homozygous for the mutation has a band of 31 nt
(Fig. 3B, lane 5) while the heterozygous carrier displays a 34, 31
and 22 nt band (Fig. 3B, lane 4). All samples contained smaller
labelled DNA fragments (<5 nt) which ran off the gel. The 22 nt
band appears less intense than the 31 or 34 nt fragments. This is
due to the different amounts of [α-32P]dCMP residues in each
fragment. The 22 nt fragment has one C residue whereas the 31
and 34 nt fragments have three C residues.
GMPD of various MHS mutations within different sequence
contexts
In order to further validate the use of the GMPD for generalised
mutation detection we demonstrate its use for the detection of four
additional RYR1 point mutations (A1565C, C1840T, G7301A and
G7297A) (reviewed in 9) in MHS. The sequence of the extended
diagnostic primers and the expected sizes of the normal and mutant
alleles for each mutation are shown (Fig. 4A). A MHN and MHS
sample for each of the above mutations was analysed by GMPD.
The normal alleles [22, 30, 34 and 37 nt (Fig. 4B, lanes 1, 5, 9
Figure 4. GMPD of MHS RYR1 A1565C, C1840T, G7301A and G7297A
mutations. (A) The labelled diagnostic primers for each mutation are enclosed
in a box. The sites of dUMP incorporation during PCR amplification are shown
in bold type along with the corresponding sizes of the expected diagnostic
fragments. (B) Untreated PCR amplification products of regions surrounding
each mutation are shown in lanes 4, 8, 12 and 16 respectively. The labelled
diagnostic primers for each mutation are shown in lanes 3, 7, 11 and 15 (21, 26,
26 and 28 nt, respectively). Lanes 1, 5, 9 and 13 shows the UDG mediated
cleavage products generated from the amplified DNA from MHN individuals
(22, 30, 34 and 37 nt, respectively). Lanes 2, 6, 10 and 14 shows the cleavage
products from MHS individuals (31, 27, 32 and 29 nt, respectively). The upper
and lower primer pairs for each mutation respectively are as follows (numbers
refer to nucleotide position within RYR1 gene): 1486–1506 and 1567–1576 (in
addition to the following intronic sequence at the 5′-end of the primer,
5′-GGGACCCCTAC-3′); 1813–1838 and 1858–1881; 7270–7293 and
7308–7333; 7270–7293 and 7299–7326.
and 13) for the A1565C, C1840T, G7301A and G7297A,
respectively] were detected in all individuals whereas the
expected mutant alleles [31, 27, 32 and 29 nt (Fig. 4B, lanes 2, 6,
10 and 14) for the A1565C, C1840T, G7301A and G7297A,
respectively] were observed in the different heterozygous MHS
individuals. 
Allele size design 
Tailoring of the size of the mutant and normal alleles generated
in the GMPD process would facilitate multiplex detection of
mutations. The use of mismatches and inosine residues in the
non-diagnostic primer in order to change the size of the normal
allele was investigated. Inosines in the template strand usually
direct the incorporation of cytosine residues into the newly
synthesised strand (14,15). The example shown is for the
G1021A mutation in MHS. Specifically, we positioned the
non-diagnostic primer so that there were no adenine residues
between the 3′-end of the primer and mutation site. Some or all
of the adenine residues within the primer were also replaced with
inosine residues or with a mismatched base. Replacement of the
penultimate 3′ adenine base in the non-diagnostic primer (upper
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Figure 5. Tailoring of the non-diagnostic primer. (A) DNA sequence of the
wild-type RYR1 gene from nucleotide 998 to 1044. Primers used in
amplification of this region are shown in lower case letters. The asterisk denotes
the end labelled diagnostic primer (lower primer). The G1021A mutation site
(G/C to A/T) is indicated by larger bold type. Primers a, b, c and d are the various
uppers primers used in the amplification reaction and contain: no inosines, a ‘g’
mismatched nucleotide, one inosine or five inosine residues respectively. All
upper primers are 20 nt in length except for primer d which is 23 nt. (B) Analysis
of fragments generated from the amplified RYR1 region 998/1001–1044 from
an MHN (lanes 1–4) and MHS (lanes 5–8) individual following UDG mediated
cleavage. The upper primer used in the amplification reactions was primer a
(lanes 1 and 5), primer b (lanes 2 and 6), primer c (lanes 3 and 7) and primer
d (lanes 4 and 8).
primer) with guanine or inosine increased the length of the normal
allele from 25 to 28 nt following glycosylase mediated cleavage
of the 47 bp amplified product (Fig. 5). Replacement of all the
adenines in the non-diagnostic primer with inosines yielded a
labelled normal allele of 47 nt that is devoid of uracil bases and
resistant to cleavage mediated by UDG (Fig. 5B, lane 4). By
contrast, the corresponding untreated mutant allele has a single
uracil in the entire 47 nt labelled strand and yields a 23 nt fragment
after UDG mediated cleavage (Fig. 5B, lane 8). This example
serves to illustrate the flexibility of primer design that is permitted
with GMPD. Importantly, the example also shows that uracil is
not incorporated opposite inosine residues in the template stand
during the amplification reaction, since following UDG mediated
cleavage, only the full size normal allele is detected if the five
adenines in the non-diagnostic primer are replaced with inosines
(Fig. 5B, lanes 4 and 8).
Solid phase GMPD
The flexibility of primer design when using GMPD and the fact
that a glycosylase resistant product from the normal allele and a
glycosylase sensitive product from the mutant allele could be
amplified readily prompted us to investigate the possibility of
adapting GMPD of the G1021A mutation to solid phase.
In this case, the lower primer was as shown in Figure 5 except
that it was biotinylated and moved 2 nt closer to the 1021 position
so that the 3′-end of the primer was next to the mutation site. This
primer was used with primer d (Fig. 5; all adenine replaced by
inosines) to amplify a 47 bp product encompassing the RYR1
G1021A mutation site from the MHN and MHS (shown to carry
the G1021A mutation) members in the pedigree shown in
Figure 2. [α-32P]dCTP was included in the amplification
reaction. The [α-32P]dCTP is incorporated into both amplified
strands but importantly can only be incorporated at, or 3′ of the
mutation site in the biotinylated strand. Following amplification,
half of the amplified 47 bp product was treated with UDG while
the remaining half of each sample was treated in an identical
manner except that UDG was omitted. Following this, the
biotinylated strand was isolated and disassociated from its
complementary strand using streptavidin coated magnetic beads
and alkali treatment. The radioactivity remaining attached to the
beads was quantified by Cerenkov counting and the results are
expressed as the percentage of total radioactive DNA remaining
bound (Table 1). In all cases, there was a clear difference between
the MHN and MHS samples. The percentage DNA remaining
bound for MHN samples varied from 90 to 99%, while MHS
samples varied from 36 to 52%. It is not clear why there is a
variation of up to 16% in the assay. This may reflect variation in
the amplification of the normal and mutant alleles or sampling
error. Nonetheless, even with a 16% variation, there is a clear
difference between the normal and mutant alleles.
Table 1.
Family member Disease status Genotypeb % Radioactivity boundc
identification no.a
1 MHS – / + 40
2 MHN – / – 97
3 MHN – / – 99
4 MHS – / + 36
5 MHN – / – 90
6 MHN – / – 91
7 MHS – / + 40
8 MHS – / + 52
ano. refers to the family member shown in the pedigree in Figure 2B.
bGenotype with respect to absence or presence of the RYR1 G1021A mutation
as determined by SSCP analysis.
cPercentage radioactivity bound is calculated as the amount of radioactivity
remaining bound to the beads following UDG mediated cleavage of the amplified
DNA divided by the amount of radioactivity remaining bound to the beads when
the amplified DNA is not treated with UDG.
DISCUSSION
In this work we describe a novel process for identification of
mutations in DNA which exploits the DNA repair enzyme UDG.
This process relies on the ability of UDG to specifically excise U
residues incorporated into a mutation site in amplified DNA.
Twelve possible point mutations can occur in DNA. Ten of these
result in the loss or gain of a T (U) residue. The remaining two
point mutations G to C and C to G do not involve a T residue. The
most common type of point mutations (and polymorphisms) in
human genetic disease result from deamination of C or 5 methyl
815
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C residues to U or T respectively, thus, C to T transitions account
for a high proportion of single point mutations (16,17). Deletion
and insertion mutations also occur frequently in DNA and all can
be detected by using GMPD. Thus, the GMPD process described
offers a means to detect most mutations in a streamlined process
with single enzyme. To detect all known mutations, it will be
necessary to detect G to C and C to G mutations. Utilisation of a
DNA-glycosylase that recognises a substrate base incorporated in
place of cytosine or guanine residues should readily allow
detection of G to C and C to G substitutions and a second
DNA-glycosylase is currently being evaluated for this purpose.
However, UDG alone is sufficient for detection of the majority of
mutations.
In this work, we have described the use of GMPD for detection
of several different point mutations and a deletion mutation
demonstrating that the method works well with different mutations
in different sequence contexts. The GMPD process is also very
flexible and versatile and facilitates multiplex mutation analysis
since large or small amplification products can be utilised and the
sizes of cleavage products can be designed to suit ones requirements
by appropriate tailoring of the diagnostic and non-diagnostic
primers. Furthermore, differential fluorescent dyes in conjunction
with differential diagnostic primer sizes should allow the analysis of
multiple mutations per electrophoresis lane. Replacement of
adenines with inosines in a primer exclude incorporation of uracil
residues in the newly synthesised DNA complementary to the
primer strand. This facilitates solid phase GMPD since UDG
resistant or sensitive strands of DNA can be amplified dependent on
presence or absence of the incorporation of a uracil residue at the
mutation site. We have successfully demonstrated such a solid phase
approach for detection of the G1021A mutation in RYR1 gene of an
MH pedigree. Although the number of samples tested here was
small, clear differences were observed between normal and mutant
alleles illustrating the potential of this approach for large scale
screening of known mutations.
The GMPD method has many attractive features which offers
significant advantages over several current technologies utilised for
detection of known mutations such as direct DNA sequencing,
restriction enzyme digestion (PCR-RFLPs), single strand
conformation analysis (SSCP), ligase chain reaction, allele specific
oligonucleotide probes, ARMS test and competitive oligonucleotide
priming (18–22). In particular, GMPD offers the specificity of direct
DNA sequencing but is a much simpler process with almost all
mutations detected using a single enzyme. The method does not rely
on heteroduplex formation but works equally well on homozygous
and heterozygous samples. The annealing of primers is not
dependent on stringent or differential hybridisation conditions. The
amplification of samples using dUTP works well with several
thermostable polymerases and overall only sequence information of
20–25 nt on either side of the mutation site is required in order to
design appropriate primers for the amplification process. The
process can be performed directly on any DNA sample and the
process is robust and requires relatively few manipulations. Solid
phase GMPD using one of the many applicable detection systems
avoids the use of time consuming gel electrophoresis and will allow
rapid and high throughput sample analysis.
The great increase in our knowledge of the human genome is
a relatively recent event, with the generation of successful
genome wide genetic maps (23,24). The availability of such dense
maps have encouraged many studies including genetic linkage of
mono- and polygenic traits. For future investigations of polygenic
traits and for generation of a human genetic map based on biallelic
polymorphisms, it will be necessary to genotype large numbers of
simple single nucleotide polymorphisms (SNP) spread throughout
the entire genome. The specificity, versatility and simplicity of the
GMPD technique should make it an attractive candidate for both
small and large scale application in the mutation detection and
polymorphism genotyping fields.
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